FDA approves CRM monitoring system

 
 
 
 - HIE
 

The FDA approved Smartview technology to remotely monitor patients with implanted cardiac rhythm management (CRM) devices. The system allows patients to transmit data electronically from implanted cardiac devices to their physicians.

The system uses Smartview and Paradym RF devices, according to manufacturer Sorin Group, which initiated its U.S. launch of the Paradym RF VR and DR implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT-D) devices in May 2012.

The Milan, Italy-based company said it was now beginning its launch of Smartview in the U.S.